SCHEMBL5861671

SCHEMBL5861671

Nc1nc(N)c2cc(Cn3c4ccccc4c4ccccc43)ccc2n1

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.50
DCPS Q96C86 1/20 0.50
DHFR P00374 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5860607 0.78 DHFR (0.55) DHFR
SCHEMBL8387208 0.76 DHFR (0.60) DCPSDHFR
SCHEMBL5355383 0.76 DHFR (0.60) DCPSDHFR
SCHEMBL27809370 0.76 DHFR (0.51) DHFR
SCHEMBL5860404 0.75 DHFR (0.55) DHFR
SCHEMBL5860714 0.75 DHFR (0.46) DCPSDHFR
SCHEMBL5862719 0.75 DHFR (0.49) DCPSDHFR
SCHEMBL4420382 0.74 DHFR (0.53) DHFR
SCHEMBL14849331 0.73 CYP19A1 (0.64) CYP19A1
SCHEMBL5348919 0.72 KDM4E (0.58) DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002541144-A 2002-12-03 JP claimed
EP-1154997-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF DANA FARBER CANCER INST INC (US) 2002-11-04 EP claimed
EP-1154997-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2001-11-21 EP claimed
WO-2000059884-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2000-10-12 WO claimed
US-7056911-B1 Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof DANA-FARBER CANCER INSTITUTE (US) 2006-06-06 US disclosed
EP-1154997-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF DANA FARBER CANCER INST INC (US) 2002-11-04 EP disclosed
EP-1154997-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2001-11-21 EP disclosed
WO-2000059884-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2000-10-12 WO disclosed